Drugmaker Daiichi-Sankyo has been granted permission in the multidistrict litigation over blood pressure drug Benicar to hire plaintiffs’ prescribing physicians as experts or consultants for the defense. But a federal judge in New Jersey drew the line at the company’s proposal to set restrictions on prescribing doctors’ ex parte communications with plaintiffs and their attorneys.

Daiichi-Sankyo said in court papers that it sought approval for the measures as a way to prevent plaintiffs counsel from “woodshedding”—manipulating their clients’ doctors’ recollection of events and tainting their eventual testimony.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]